Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MabionWAR:MAB +1.08%31 Receivables Turnover is 1.65 as of Mar. 2026. GuruFocus rates WAR:MAB with a GF Score™ of 31/100 and a GF Value™ of zł2.07 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 841 Biotechnology companies, Mabion ranks better than 82.28% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Mabion's Revenue for the
three
months ended in Mar. 2026 was zł4.57 Mil. Mabion's average Accounts Receivable for the
three
months ended in Mar. 2026 was zł2.78 Mil.
Hence, Mabion's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.65.
Mabion (WAR:MAB) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Mabion Receivables Turnover Related Terms
Mabion Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Mabion's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:MAB vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Mabion's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mabion Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mabion's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Mabion's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mabion (WAR:MAB) has a Receivables Turnover of 1.65 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Mabion and its competitors. According to the industry distribution chart, Mabion ranks #149 out of 841 companies in the Biotechnology industry, placing it in the top 17.7%.
Is Mabion's Receivables Turnover too high?
Mabion's current Receivables Turnover is 1.65. The Biotechnology industry median Receivables Turnover is 5.28. Mabion's value of 1.65 is 68.8% below this industry median. Based on the distribution chart, Mabion ranks #149 out of 841 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Mabion has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mabion's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mabion ranks #149 out of 841 companies for Receivables Turnover. This places Mabion in the top 18% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.28. Mabion's value of 1.65 is 68.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mabion's current Receivables Turnover of 1.65 is 68.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Mabion and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mabion's current Receivables Turnover is 1.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mabion stock overvalued right now?
Based on GuruFocus' analysis, Mabion (WAR:MAB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł2.07, compared to a current price of zł7.50 — trading 262.3% above its estimated fair value. The current Receivables Turnover is 1.65 and 68.8% below the Biotechnology industry median of 5.28. Mabion's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Mabion (WAR:MAB), the current Receivables Turnover is 1.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mabion (WAR:MAB) Overvalued in 2026?
Based on GuruFocus' analysis, Mabion stock appears to be overvalued.
The current stock price of zł7.50 is trading 262.3% above its estimated GF Value™ of zł2.07.
GuruFocus considers Mabion to be Significantly Overvalued.
Key valuation signals for WAR:MAB:
Receivables Turnover: 1.65
GF Value™: zł2.07 vs. price of zł7.50 (262.3% above fair value)
Industry Position: 68.8% below the Biotechnology median (#149 of 841)
No single metric tells the full story. See the WAR:MAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.
31GF Score
Get the complete analysis for WAR:MAB
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:MAB has been successfully added to your 
